quetiapine

• Abnormally high prolactin

  no effect, n = 42

  abnormally high prolactin (1 RCT, n=42, RR 0.10 CI 0.01 to 1.77)

  PMID:20091600 · one of two readings recorded this

• Akathisia as measured by scale

  no effect, n = 700

  akathisia (BAS, 2 RCTs, n=700, WMD −0.73 CI −2.0 to 0.54)

  PMID:20091600 · one of two readings recorded this

• Akathisia

  no effect, n = 135

  akathisia (2 RCTs, n=135, RR 0.4 CI 0.08 to 1.99)

  PMID:20091600 · one of two readings recorded this

• Akathisia

  no effect, n = 1277

  akathisia (6 RCTs, n=1277, RR 0.98 CI 0.68 to 1.4)

  PMID:20091600 · one of two readings recorded this

• Akathisia

  no effect, n = 2170

  akathisia (6 RCTs, n=2170, RR 0.62 CI 0.34 to 1.13)

  PMID:20091600 · one of two readings recorded this

• Akathisia

  no effect, n = 754

  akathisia (2 RCTs, n=754, RR 0.78 CI 0.42 to 1.45)

  PMID:20091600 · one of two readings recorded this

• Akinesia

  no effect, n = 267

  akinesia (1 RCT, n=267, RR 1.02 CI 0.67 to 1.56)

  PMID:20091600 · one of two readings recorded this

• Akinesia

  no effect, n = 267

  akinesia (1 RCT, n=267, RR 0.91 CI 0.61 to 1.37)

  PMID:20091600 · one of two readings recorded this

• Amenorrhoea

  no effect, n = 252

  amenorrhoea (3 RCTs, n=252, RR 0.66 CI 0.36 to 1.21)

  PMID:20091600 · one of two readings recorded this

• Amenorrhoea

  decreases, n = 359

  amenorrhoea (4 RCTs, n=359, RR 0.47 CI 0.28 to 0.79, NNT not estimable)

  PMID:20091600 · one of two readings recorded this

• Amenorrhoea

  no effect, n = 138

  amenorrhoea (1 RCT, n=138, RR 0.43 CI 0.15 to 1.24)

  PMID:20091600 · one of two readings recorded this

• Any extrapyramidal symptom

  no effect, n = 245

  any extrapyramidal symptom (2 RCTs, n=245, RR 1.62 CI 0.72 to 3.67)

  PMID:20091600 · one of two readings recorded this

• Any extrapyramidal symptoms

  no effect, n = 232

  (1 RCT, n=232, RR 2.02 CI 0.66 to 6.17)

  PMID:20091600 · one of two readings recorded this

• Cardiac effects: ECG abnormalities

  decreases, n = 72

  There was a significant difference favouring quetiapine (1 RCT, n=72, RR 0.13 CI 0.02 to 0.95, NNH 5 CI 3 to 20)

  PMID:20091600 · one of two readings recorded this

• Cholesterol, mean change from baseline

  no effect, n = 986

  Overall data on cholesterol change from baseline did not show a statistically significant difference between groups (4 RCTs, n=986, WMD −4.69 CI −13.84 to 4.45)

  PMID:20091600 · one of two readings recorded this

• Cholesterol, mean change from baseline

  increases, n = 1433

  There was a significant difference favouring risperidone (5 RCTs, n=1433, WMD 8.61 CI 4.66 to 12.56)

  PMID:20091600 · one of two readings recorded this

• Cholesterol, mean change from baseline

  increases, n = 754

  Ziprasidone was associated with significantly less cholesterol increase than quetiapine (2 RCTs, n=754, WMD 16.01 CI 8.57 to 23.46)

  PMID:20091600 · one of two readings recorded this

• Cholesterol, mean change from baseline

  decreases, n = 643

  Excluding this study revealed a significant difference in favour of quetiapine (3 RCTs, n=643, WMD −7.84 CI −14.12 to −1.57)

  PMID:20091600 · one of two readings recorded this

• Cholesterol: number with abnormally high cholesterol increase

  no effect, n = 267

  There was no significant difference (1 RCT, n=267, RR 0.99 CI 0.59 to 1.68)

  PMID:20091600 · one of two readings recorded this

• Cholesterol: number with significant cholesterol increase

  no effect, n = 940

  There was no significant difference (2 RCTs, n=940, RR 1.27 CI 0.72 to 2.24)

  PMID:20091600 · one of two readings recorded this

• Death

  no effect, n = 1410

  There was no significant difference (4 RCTs, n=1410, RR 0.74 CI 0.13 to 4.23)

  PMID:20091600 · one of two readings recorded this

• Death

  no effect, n = 3066

  There was no significant difference (7 RCTs, n=3066, RR 0.73 CI 0.17 to 3.09)

  PMID:20091600 · one of two readings recorded this

• Death

  no effect, n = 754

  There was no significant difference (2 RCTs, n=754, RR 0.41 CI 0.05 to 3.15)

  PMID:20091600 · one of two readings recorded this

• Dyskinesia as measured by scale

  no effect, n = 958

  dyskinesia (AIMS, 2 RCTs, n=958, WMD −0.34 CI-0.75 to 0.08)

  PMID:20091600 · one of two readings recorded this

• Dysmenorrhoea

  no effect, n = 163

  dysmenorrhoea (1 RCT, n=163, RR 0.45 CI 0.08 to 2.38)

  PMID:20091600 · one of two readings recorded this

• Dystonia

  no effect, n = 42

  dystonia (1 RCT, n=42, RR 4.57 CI 0.23 to 89.72)

  PMID:20091600 · one of two readings recorded this

• Dystonia

  decreases, n = 673

  dystonia (1 RCT, n= 673, RR 0.06 CI 0.01 to 0.41, NNH 20 CI 13 to 33)

  PMID:20091600 · one of two readings recorded this

• Extrapyramidal side effects as measured by scale

  decreases, n = 1077

  Quetiapine produced fewer extrapyramidal side effects than risperidone according to the Simpson-Angus Scale (5 RCTs, n= 1077, WMD −0.59 CI −1.16 to −0.02)

  PMID:20091600 · one of two readings recorded this

• Extrapyramidal symptoms

  decreases, n = 872

  (2 RCTs, n=872, RR 0.59 CI 0.43 to 0.81, NNH 14 CI 8 to 33)

  PMID:20091600 · one of two readings recorded this

• Galactorrhoea

  no effect, n = 1025

  galactorrhoea (4 RCTs, n=1025, RR 0.66 CI 0.25 to 1.73)

  PMID:20091600 · one of two readings recorded this

• Galactorrhoea

  decreases, n = 478

  galactorrhoea (5 RCTs, n=478, RR 0.38 CI 0.17 to 0.84, NNT 25 CI 13 to 100)

  PMID:20091600 · one of two readings recorded this

• Galactorrhoea

  no effect, n = 202

  galactorrhoea (2 RCTs, n=202, RR 0.68 CI 0.23 to 2.01)

  PMID:20091600 · one of two readings recorded this

• General functioning: average endpoint total score

  increases, n = 278

  There was a significant difference in favour of olanzapine (1 RCT, n=278, WMD 3.8 CI 0.77 to 6.83)

  PMID:20091600 · one of two readings recorded this

• General mental state: average endpoint score

  no effect, n = 232

  Four short term studies did not indicate a significant difference (4 RCTs, n=232, WMD −0.5 CI −2.85 to 1.86)

  PMID:20091600 · one of two readings recorded this

• General mental state: average endpoint score

  increases, n = 1449

  There was a significant difference favouring olanzapine (10 RCTs, n=1449, WMD 3.66 CI 1.93 to 5.39)

  PMID:20091600 · one of two readings recorded this

• General mental state: average endpoint score

  increases, n = 1953

  There was a significant difference in favour of risperidone: overall (9 RCTs, n=1953, WMD 3.09 CI 1.01 to 5.16)

  PMID:20091600 · one of two readings recorded this

• General mental state: average endpoint score

  no effect, n = 198

  (medium term data) n=198, WMD 3.7 CI −2.97 to 10.37

  PMID:20091600 · one of two readings recorded this

• General mental state: no clinically important change (less than 20% BPRS total score reduction)

  no effect, n = 25

  There was no significant difference (1 RCT, n=25, RR 0.98 CI 0.63 to 1.52)

  PMID:20091600 · one of two readings recorded this

• General mental state: no clinically important change (less than 30% PANSS total score reduction)

  no effect, n = 984

  There was no significant difference (2 RCTs, n=984, RR 1.11 CI 0.87 to 1.42)

  PMID:20091600 · one of two readings recorded this

• General mental state: no clinically important change (less than 50% PANSS total score reduction)

  no effect, n = 63

  There was no clear difference to be found (1 RCT, n=63, RR 1.07 CI 0.53 to 2.14)

  PMID:20091600 · one of two readings recorded this

• General mental state: no clinically important change (less than 50% PANSS total score reduction)

  no effect, n = 42

  There was no significant difference (1 RCT, n=42, RR 0.91 CI 0.54 to 1.53)

  PMID:20091600 · one of two readings recorded this

• Glucose, change from baseline

  decreases, n = 986

  The mean increase of glucose from baseline was lower in the quetiapine group than in the olanzapine group (4 RCTs, n=986, WMD −9.32 CI −17.82 to −0.82)

  PMID:20091600 · one of two readings recorded this

• Glucose, mean change from baseline

  no effect, n = 1436

  There was no significant difference (5 RCTs, n=1436, WMD −0.04 CI −2.92 to 2.83)

  PMID:20091600 · one of two readings recorded this

• Glucose, mean change from baseline

  no effect, n = 754

  There was no significant difference (2 RCTs, n=754, WMD 3.1 CI −3.99 to 10.19)

  PMID:20091600 · one of two readings recorded this

• Glucose: number with abnormally high fasting glucose

  no effect, n = 267

  There was no significant difference (1 RCT, n=267, RR 0.71 CI 0.33 to 1.54)

  PMID:20091600 · one of two readings recorded this

• Glucose: number with abnormally high fasting glucose

  no effect, n = 940

  There was no significant difference (2 RCTs, n=940, RR 1.39 CI 0.56 to 3.45)

  PMID:20091600 · one of two readings recorded this

• Gynaecomastia

  no effect, n = 267

  gynaecomastia (1 RCT, n=267, RR 0.33 CI 0.09 to 1.20)

  PMID:20091600 · one of two readings recorded this

• Gynaecomastia

  decreases, n = 78

  gynaecomastia (1 RCT, n=78, RR 0.23 CI 0.07 to 0.75, NNT 4 CI 2 to 11)

  PMID:20091600 · one of two readings recorded this

• Important decline in white blood cells

  no effect, n = 33

  There was no significant difference (1 RCT, n=33, RR 0.19 CI 0.01 to 3.88)

  PMID:20091600 · one of two readings recorded this

• Important decline in white blood cells

  no effect, n = 673

  There was no significant difference (1 RCT, n=673, RR 2.97 CI 0.12 to 72.73)

  PMID:20091600 · one of two readings recorded this

• Leaving the studies early for any reason, overall attrition (all arms pooled)

  A major problem, however, was the very high attrition which in nine studies was higher than 30% (57.6% overall)

  PMID:20091600 · one of two readings recorded this

• Leaving the study early due to adverse events

  no effect, n = 72

  due to adverse events (1 RCT, n=72, RR 0.14 CI 0.01 to 2.6)

  PMID:20091600 · one of two readings recorded this

• Leaving the study early due to adverse events

  no effect, n = 1573

  but not due to adverse events (12% versus 11%, 8 RCTs, n=1573, RR 0.90 CI 0.69 to 1.18)

  PMID:20091600 · one of two readings recorded this

• Leaving the study early due to adverse events

  no effect, n = 1851

  or due to adverse events (11% versus 9%, 7 RCTs, n=1851, RR 1.19 CI 0.78 to 1.8)

  PMID:20091600 · one of two readings recorded this

• Leaving the study early due to adverse events

  no effect, n = 722

  due to adverse events (2 RCTs, n=722, RR 1.04 CI 0.72 to 1.49)

  PMID:20091600 · one of two readings recorded this

• Leaving the study early due to any reason

  no effect, n = 95

  due to any reason (2 RCTs, n=95, RR 0.67 CI 0.18 to 2.43)

  PMID:20091600 · one of two readings recorded this

• Leaving the study early due to any reason

  increases, n = 1651

  Fewer participants in the olanzapine group (57%) compared with the quetiapine group (70%) left the studies early because of ‘any reason’ (10 RCTs, n=1651, RR 1.22 CI 1.13 to 1.32, NNH 10 CI 6 to 33)

  PMID:20091600 · one of two readings recorded this

• Leaving the study early due to any reason

  no effect, n = 2278

  There was no significant difference in the number of participants leaving the studies early due to any reason (quetiapine 57%, risperidone 54%, 10 RCTs, n=2278, RR 1.06 CI 0.98 to 1.15)

  PMID:20091600 · one of two readings recorded this

• Leaving the study early due to any reason

  no effect, n = 722

  due to any reason (2 RCTs, n=722, RR 1.05 CI 0.97 to 1.13)

  PMID:20091600 · one of two readings recorded this

• Leaving the study early due to inefficacy

  increases, n = 1563

  or ‘inefficacy’ (14% versus 25%, 8 RCTs, n=1563, RR 1.8 CI 1.42 to 2.27, NNH 11 CI 6 to 50)

  PMID:20091600 · one of two readings recorded this

• Leaving the study early due to inefficacy

  no effect, n = 1851

  Leaving early due to inefficacy showed an almost significant superiority of risperidone (24% versus 19%, 7 RCTs, n=1851, RR 1.26 CI 0.99 to 1.61)

  PMID:20091600 · one of two readings recorded this

• Leaving the study early due to inefficacy

  no effect, n = 722

  due to inefficacy of treatment (2 RCTs, n=722, RR 1.14 CI 0.89 to 1.47)

  PMID:20091600 · one of two readings recorded this

• Mean change of QTc interval from baseline

  increases, n = 643

  There was a significant difference favouring olanzapine (3 RCTs, n=643, WMD 4.81 CI 0.34 to 9.28)

  PMID:20091600 · one of two readings recorded this

• Mean change of QTc interval from baseline

  no effect, n = 940

  Overall there was no significant difference (3 RCT, n= 940, WMD 2.21 CI −5.05 to 9.48)

  PMID:20091600 · one of two readings recorded this

• Mean change of QTc interval

  no effect, n = 549

  There was no significant difference (2 RCTs, n=549, WMD 3.41 CI −1.37 to 8.18)

  PMID:20091600 · one of two readings recorded this

• Negative symptoms: average endpoint score, percent change from baseline

  no effect, n = 30

  There was no significant difference (1 RCT, n=30, WMD 2.46 CI −31.9 to 36.82)

  PMID:20091600 · one of two readings recorded this

• Negative symptoms: average endpoint score

  decreases, n = 142

  Two small Chinese studies showed a significant superiority of quetiapine (2 RCTs, n=142, WMD −2.23 CI −3.48 to −0.99)

  PMID:20091600 · one of two readings recorded this

• Negative symptoms: average endpoint score

  no effect, n = 679

  There was no significant difference (7 RCTs, n=679, WMD 0.41 CI −0.36 to 1.18)

  PMID:20091600 · one of two readings recorded this

• Negative symptoms: average endpoint score

  no effect, n = 956

  short term studies, 4 RCTs, n=956, WMD −1.46 CI −4.11 to 1.19

  PMID:20091600 · one of two readings recorded this

• Negative symptoms: average endpoint score

  no effect, n = 198

  There was no significant difference (1 RCT, n=198, WMD 1.6 CI −0.34 to 3.54)

  PMID:20091600 · one of two readings recorded this

• Negative symptoms: average endpoint score

  increases, n = 1139

  Excluding a small outlier study in a sensitivity analysis there was a significant superiority of risperidone (6 RCTs, n=1139, WMD 0.79 CI 0.04 to 1.54)

  PMID:20091600 · one of two readings recorded this

• Negative symptoms: no clinically important change (less than 20% SANS total score reduction)

  no effect, n = 30

  There was no significant difference (1 RCT, n=30, RR 1.5 CI 0.53 to 4.26)

  PMID:20091600 · one of two readings recorded this

• Negative symptoms: no clinically important change (less than 40% PANSS negative score reduction)

  no effect, n = 673

  There was no significant difference (1 RCT, n=673, RR 0.98 CI 0.93 to 1.04)

  PMID:20091600 · one of two readings recorded this

• Negative symptoms: no clinically important change (less than 50% SANS total score reduction)

  no effect, n = 72

  There was no significant difference (1 RCT, n=72, RR 0.94 CI 0.78 to 1.13)

  PMID:20091600 · one of two readings recorded this

• No clinically important change in global state (as defined by the original studies)

  no effect, n = 72

  There was no significant difference (1 RCT, n=72, RR 0.94 CI 0.74 to 1.18)

  PMID:20091600 · one of two readings recorded this

• No clinically important change in global state (as defined by the original studies)

  no effect, n = 309

  There was no significant difference (2 RCTs, n=309, RR 1.18 CI 0.89 to 1.57)

  PMID:20091600 · one of two readings recorded this

• No clinically important change in global state (as defined by the original studies)

  no effect, n = 1374

  There was a small superiority of risperidone which did not reach statistical significance (4 RCTs, n=1374, RR 1.16 CI 0.99 to 1.35)

  PMID:20091600 · one of two readings recorded this

• No clinically significant response (as defined by the original studies)

  no effect, n = 72

  There was no significant difference (1 RCT, n=72, RR 0.94 CI 0.78 to 1.13)

  PMID:20091600 · one of two readings recorded this

• No clinically significant response (as defined by the original studies)

  no effect, n = 339

  There was no significant difference (3 RCTs, n=339, RR 1.11 CI 0.86 to 1.43)

  PMID:20091600 · one of two readings recorded this

• No clinically significant response (as defined by the original studies)

  no effect, n = 103

  (n=103, RR 1.18 CI 0.87 to 1.6)

  PMID:20091600 · one of two readings recorded this

• No clinically significant response (as defined by the original studies)

  increases, n = 177

  reported a significant difference in favour of risperidone (n=177, RR 1.27 CI 1.05 to 1.55)

  PMID:20091600 · one of two readings recorded this

• No clinically significant response (as defined by the original studies)

  no effect, n = 495

  (n=495, RR 1.0 CI 0.91 to 1.09)

  PMID:20091600 · one of two readings recorded this

• Parkinsonism

  no effect, n = 40

  parkinsonism (1 RCT, n=40, RR 0.66 CI 0.18 to 2.41)

  PMID:20091600 · one of two readings recorded this

• Parkinsonism

  no effect, n = 44

  parkinsonism (1 RCT, n=44, RR 0.06 CI 0.0 to 0.96)

  PMID:20091600 · one of two readings recorded this

• Participants with at least one adverse effect

  decreases, n = 63

  There was a significant difference, based on data from, favouring the treatment group (1 RCT, n=63, RR 0.42 CI 0.26 to 0.66, NNH 2 CI 1 to 3)

  PMID:20091600 · one of two readings recorded this

• Participants with at least one adverse effect

  no effect, n = 1269

  There was no significant difference (6 RCTs, n=1269, RR 0.97 CI 0.88 to 1.06)

  PMID:20091600 · one of two readings recorded this

• Participants with at least one adverse effect

  no effect, n = 2226

  There was no significant difference (8 RCTs, n=2226, RR 1.04 CI 0.93 to 1.17)

  PMID:20091600 · one of two readings recorded this

• Participants with at least one adverse effect

  no effect, n = 754

  There was no significant difference (2 RCTs, n=754, RR 1.03 CI 0.91 to 1.17)

  PMID:20091600 · one of two readings recorded this

• Positive symptoms: average endpoint score, percentage change from baseline

  increases, n = 30

  There was a significant difference favouring olanzapine (1 RCT, n=30, WMD 40.84 CI 23.97 to 57.71)

  PMID:20091600 · one of two readings recorded this

• Positive symptoms: average endpoint score

  no effect, n = 142

  There was no significant difference (2 RCTs, n=142, WMD −0.7 CI −2.07 to 0.68)

  PMID:20091600 · one of two readings recorded this

• Positive symptoms: average endpoint score

  increases, n = 679

  There was a significant difference in favour of olanzapine (7 RCTs, n=679, WMD 1.8 CI 1.02 to 2.59)

  PMID:20091600 · one of two readings recorded this

• Positive symptoms: average endpoint score

  increases, n = 1264

  There was a significant difference favouring risperidone overall (7 RCTs, n=1264, WMD 1.82 CI 1.16 to 2.48)

  PMID:20091600 · one of two readings recorded this

• Positive symptoms: average endpoint score

  no effect, n = 198

  There was no significant difference (1 RCT, n=198, WMD 0.0 CI −2.18 to 2.18)

  PMID:20091600 · one of two readings recorded this

• Positive symptoms: no clinically important change (less than 20% SAPS total score reduction)

  no effect, n = 30

  There was no difference identified with confidence (1 RCT, n=30, RR 15.0 CI 0.93 to 241.2)

  PMID:20091600 · one of two readings recorded this

• Positive symptoms: no clinically important change (less than 40% PANSS positive score reduction)

  no effect, n = 673

  There was no significant difference (1 RCT, n=673, RR 1.00 CI 0.9 to 1.12)

  PMID:20091600 · one of two readings recorded this

• Prolactin, change from baseline

  decreases, n = 1021

  Quetiapine was associated with less prolactin increase than olanzapine (5 RCTs, n=1021, RR −5.89 CI −11.62 to −0.16)

  PMID:20091600 · one of two readings recorded this

• Prolactin, change from baseline

  decreases, n = 1731

  (6 RCTs, n=1731, WMD −35.28 CI −44.36 to −26.19

  PMID:20091600 · one of two readings recorded this

• Prolactin, mean change from baseline

  decreases, n = 754

  There was a significant difference in favour of quetiapine (2 RCTs, n=754, WMD −4.77 CI −8.16 to −1.37)

  PMID:20091600 · one of two readings recorded this

• QTc prolongation (number of participants)

  no effect, n = 673

  There was no significant difference (1 RCT, n=673, RR 12.96 CI 0.73 to 229.17)

  PMID:20091600 · one of two readings recorded this

• QTc prolongation (number of participants)

  no effect, n = 1351

  There was no significant difference (2 RCTs, n=1351, RR 0.87 CI 0.29 to 2.55)

  PMID:20091600 · one of two readings recorded this

• QTc prolongation (number of participants)

  no effect, n = 522

  There was no significant difference (1 RCT, n=522, RR 1.65 CI 0.34 to 8.08)

  PMID:20091600 · one of two readings recorded this

• Quality of life: average endpoint score

  no effect, n = 25

  There was no significant difference (1 RCT, n=25, WMD −0.5 CI −13.87 to 12.87)

  PMID:20091600 · one of two readings recorded this

• Quality of life: average endpoint total score

  no effect, n = 286

  There was no significant difference (1 RCT, n=286, WMD 1.8 CI −2.42 to 6.02)

  PMID:20091600 · one of two readings recorded this

• Rigor

  no effect, n = 63

  rigor (1 RCT, n=63, RR 1.94 CI 0.18 to 20.3)

  PMID:20091600 · one of two readings recorded this

• Sedation

  decreases, n = 135

  Fewer participants in the quetiapine group reported this outcome (2 RCTs, n=135, RR 0.22 CI 0.11 to 0.47, NNH 3 CI 2 to 8)

  PMID:20091600 · one of two readings recorded this

• Sedation

  no effect, n = 1615

  There was no significant difference (7 RCTs, n=1615, RR 0.97 CI 0.78 to 1.2)

  PMID:20091600 · one of two readings recorded this

• Sedation

  increases, n = 2226

  There was a significant difference favouring risperidone (8 RCTs, n=2226, RR 1.21 CI 1.06 to 1.38, NNH 20 CI 11 to 50)

  PMID:20091600 · one of two readings recorded this

• Sedation

  increases, n = 754

  Significantly fewer participants in the ziprasidone group than in the quetiapine group felt sedated (2 RCTs, n=754, RR 1.36 CI 1.04 to 1.77, NNH 14 CI 7 to 100)

  PMID:20091600 · one of two readings recorded this

• Seizures

  no effect, n = 40

  There was no significant difference (1 RCT, n=40, RR 3.3 CI 0.14 to 76.46)

  PMID:20091600 · one of two readings recorded this

• Service use: number of participants re-hospitalised

  increases, n = 876

  There was a significant difference favouring olanzapine (2 RCTs, n=876, RR 1.79 CI 1.30 to 2.47, NNH 11 CI 7 to 25)

  PMID:20091600 · one of two readings recorded this

• Service use: number of participants re-hospitalised

  no effect, n = 877

  The difference almost reached statistical significance with a slight benefit for the risperidone group (2 RCTs, n=877, RR 1.34 CI 1.0 to 1.79)

  PMID:20091600 · one of two readings recorded this

• Service use: number of participants re-hospitalised

  no effect, n = 754

  There was no significant difference neither in the overall analysis (2 RCTs, n=754, RR 1.17 CI 0.85 to 1.59)

  PMID:20091600 · one of two readings recorded this

• Sexual dysfunction

  decreases, n = 1177

  Fewer participants in the quetiapine group suffered from sexual dysfunction (4 RCTs, n=1177, RR 0.8 CI 0.64 to 0.99, NNH 20 CI 10 to 100)

  PMID:20091600 · one of two readings recorded this

• Sexual dysfunction

  no effect, n = 2157

  Data on sexual dysfunction showed an almost significant superiority of quetiapine (6 RCTs, n=2157, RR 0.70 CI 0.48 to 1.01)

  PMID:20091600 · one of two readings recorded this

• Sexual dysfunction

  no effect, n = 754

  sexual dysfunction (2 RCTs, n=754, RR 0.96 CI 0.64 to 1.42)

  PMID:20091600 · one of two readings recorded this

• Tremor

  no effect, n = 135

  tremor (2 RCTs, n=135, RR 0.99 CI 0.29 to 3.34)

  PMID:20091600 · one of two readings recorded this

• Tremor

  no effect, n = 44

  tremor (1 RCT, n=44, RR 0.39 CI 0.12 to 1.31)

  PMID:20091600 · one of two readings recorded this

• Use of antiparkinson medication at least once

  decreases, n = 1090

  Fewer participants in the quetiapine group used antiparkinson medication at least once (6 RCTs, n=1090, RR 0.49 CI 0.3 to 0.79, NNH 25 CI 14 to 100)

  PMID:20091600 · one of two readings recorded this

• Use of antiparkinson medication at least once

  decreases, n = 1715

  use of antiparkinson medication at least once (6 RCTs, n=1715, RR 0.5 CI 0.3 to 0.86, NNH 20 CI 10 to 100)

  PMID:20091600 · one of two readings recorded this

• Use of antiparkinson medication at least once

  decreases, n = 522

  Significantly fewer people in the quetiapine group used antiparkinson medication at least once (1 RCT, n=522, RR 0.43 CI 0.2 to 0.93)

  PMID:20091600 · one of two readings recorded this

• Weight gain: 7% or more gain of total body weight

  no effect, n = 1942

  There was no significant difference (7 RCTs, n=1942, RR 0.97 CI 0.82 to 1.14)

  PMID:20091600 · one of two readings recorded this

• Weight gain: 7% or more gain of total body weight

  increases, n = 754

  Significantly more participants in the quetiapine group than in the ziprasidone group gained weight (2 RCTs, n=754, RR 2.22 CI 1.35 to 3.63, NNH 13 CI 8 to 33)

  PMID:20091600 · one of two readings recorded this

• Weight gain, change from baseline

  no effect, n = 27

  One small study reported a trend in favour of quetiapine (1 RCT, n=27, WMD −2.11 CI −4.3 to 0.08)

  PMID:20091600 · one of two readings recorded this

• Weight gain, change from baseline

  decreases, n = 1173

  Overall participants in the quetiapine group gained less weight than in the olanzapine group (7 RCT, n=1173, WMD −2.68 CI −4.26 to −1.10)

  PMID:20091600 · one of two readings recorded this

• Weight gain, change from baseline

  no effect, n = 466

  There was a superiority of ziprasidone which almost reached statistical significance (1 RCT, n= 466, WMD 1.2 CI −0.05 to 2.45)

  PMID:20091600 · one of two readings recorded this

• Weight gain, mean change from baseline

  no effect, n = 1446

  (7 RCTs, n=1446, WMD 0.71 CI −1.04 to 2.47)

  PMID:20091600 · one of two readings recorded this

• Weight gain (number of participants with significant weight gain)

  no effect, n = 135

  There was no significant difference (2 RCTs, n=135, RR 0.53 CI 0.25 to 1.11)

  PMID:20091600 · one of two readings recorded this

• Weight gain (significant weight gain, number of participants)

  decreases, n = 1667

  Fewer participants in the quetiapine group had a significant weight gain (8 RCTs, n=1667, RR 0.68 CI 0.51 to 0.92, NNH not estimable)

  PMID:20091600 · one of two readings recorded this

• Clinical response rate (>=50% reduction in MADRS total score)

  increases

  The pooled response rate of the quetiapine -treated group was significantly greater than that of the placebo-treated group [RR (95%CI) of 1.44 (1.26, 1.64), I2 = 0%]

  PMID:23017200 · one of two readings recorded this

• Discontinuation due to adverse events (tolerability)

  increases

  the pooled discontinuation rate due to adverse events in the quetiapine group was significantly higher than that of the placebo group [RR (95%CI) of 2.90 (1.87, 4.48), I2 = 0%]

  PMID:23017200 · one of two readings recorded this

• Mean change in HAM-D score

  decreases

  The pooled mean change HAM-D score of the quetiapine-treated group was also significantly higher than that of the placebo-treated group [WMD (95%CI) of -2.46 (-3.47, -1.45), I2 = 89%]

  PMID:23017200 · one of two readings recorded this

• mean change in Hamilton Depression Rating Scale (HAM-D) score, quetiapine XR vs placebo

  WMD -2.46 (-3.47, -1.45), I2 = 89%

  Not recorded as a finding: The sentence says the change score was 'significantly higher' while the WMD is negative; direction of the HDRS total score itself is carried only by a signed estimate, so no direction word supports it

  The pooled mean change HAM-D score of the quetiapine-treated group was also significantly higher than that of the placebo-treated group [WMD (95%CI) of -2.46 (-3.47, -1.45), I2 = 89%] (see Figure 5).

  PMID:23017200 · one of two readings recorded this

• Mean change in MADRS score

  decreases

  The pooled mean change MADRS score of the quetiapine-treated group was significantly higher than that of the placebo-treated group [WMD (95%CI) of -3.37 (-3.95, -2.79), I2 = 0%]

  PMID:23017200 · one of two readings recorded this

• mean change in Montgomery-Asberg Depression Rating Scale (MADRS) score

  WMD -3.37 (-3.95, -2.79), I2 = 0%

  Not recorded as a finding: no MADRS outcome node

  The pooled mean change MADRS score of the quetiapine-treated group was significantly higher than that of the placebo-treated group [WMD (95%CI) of -3.37 (-3.95, -2.79), I2 = 0%] (see Figure 4).

  PMID:23017200 · one of two readings recorded this

• Mean change in sleep quality

  decreases

  the pooled mean change Pittsburgh Sleep Quality Index (PSQI) score of the quetiapine-treated group was also significantly higher than that of the placebo-treated group [WMD (95%CI) of -1.21 (-1.81, -0.61), I2 = 48%]

  PMID:23017200 · one of two readings recorded this

• mean change MADRS score, quetiapine versus placebo, pooled WMD

  decreases, WMD -3.37 (-3.95, -2.79)

  Not recorded as a finding: No outcome node for MADRS

  The pooled mean change MADRS score of the quetiapine-treated group was significantly higher than that of the placebo-treated group [WMD (95%CI) of -3.37 (-3.95, -2.79), I2 = 0%] (see Figure 4).

  PMID:23017200 · one of two readings recorded this

• Number needed to treat for response

  According to the pooled response rate obtained from all trials, the NNT (95%CI) was 7.2 (5.2-11.7)

  PMID:23017200 · one of two readings recorded this

• Overall discontinuation rate (acceptability)

  no effect

  The pooled overall discontinuation rate of the quetiapine group was not significantly different from that of the placebo group [RR (95%CI) of 1.16 (0.97, 1.39), I2 = 0%]

  PMID:23017200 · one of two readings recorded this

• overall discontinuation rate, quetiapine versus placebo

  no effect, RR 1.16 (0.97, 1.39)

  Not recorded as a finding: No outcome node for all-cause discontinuation

  The pooled overall discontinuation rate of the quetiapine group was not significantly different from that of the placebo group [RR (95%CI) of 1.16 (0.97, 1.39), I2 = 0%].

  PMID:23017200 · one of two readings recorded this

• overall discontinuation rate, quetiapine vs placebo

  no effect, RR 1.16 (0.97, 1.39)

  Not recorded as a finding: no all-cause discontinuation node (only withdrawal due to adverse events exists)

  The pooled overall discontinuation rate of the quetiapine group was not significantly different from that of the placebo group [RR (95%CI) of 1.16 (0.97, 1.39), I2 = 0%].

  PMID:23017200 · one of two readings recorded this

• Remission rate (MADRS total score <=8)

  increases

  The pooled remission rate of the quetiapine-treated group was also significantly greater than that of the placebo-treated group [RR (95%CI) of 1.37 (1.12, 1.68), I2 = 0%]

  PMID:23017200 · one of two readings recorded this

• Abnormal ECG

  decreases, n = 165

  less abnormal ECG (2 RCTs, n = 165, RR 0.38 CI 0.16 to 0.92, NNTH 8, CI 4 to 55)

  PMID:23728667 · one of two readings recorded this

• Adverse effects (overall)

  decreases, n = 1985

  quetiapine might cause fewer adverse effects (9 RCTs, n = 1985, RR 0.76 CI 0.64 to 0.90 number needed to treat to induce harm (NNTH) 10, CI 8 to 17)

  PMID:23728667 · one of two readings recorded this

• General psychopathology

  no effect, n = 1569

  General psychopathology was equivocal (PANSS general psychopathology subscore: 18 RCTs, n = 1569, MD -0.20 CI -0.83 to 0.42)

  PMID:23728667 · one of two readings recorded this

• Leaving the study early due to adverse events

  decreases, n = 3010

  fewer participants in the quetiapine group left the studies early due to adverse events (15 RCTs, n = 3010, RR 0.48 CI 0.30 to 0.77)

  PMID:23728667 · one of two readings recorded this

• Leaving the study early due to any reason

  no effect, n = 3576

  no significant difference between groups was apparent for leaving early due to any reason (23 RCTs n = 3576 RR 0.91 CI 0.81 to 1.01, moderate quality evidence)

  PMID:23728667 · one of two readings recorded this

• Negative symptoms

  decreases, n = 1934

  quetiapine was statistically significantly more efficacious for negative symptoms (PANSS negative subscore: 22 RCTs, n = 1934, MD -0.82 CI -1.59 to -0.04, moderate quality evidence)

  PMID:23728667 · one of two readings recorded this

• Overall extrapyramidal effects

  decreases

  fewer overall extrapyramidal effects (8 RCTs, n = 1,095, RR 0.17 CI 0.09 to 0.32, NNTH 3, CI 3 to 3, moderate quality evidence)

  PMID:23728667 · one of two readings recorded this

• Overall global state (no clinically significant response)

  no effect, n = 1607

  Overall global state was similar between groups (no clinically significant response; 16 RCTs, n = 1607, RR 0.96 CI 0.75 to 1.23, moderate quality evidence)

  PMID:23728667 · one of two readings recorded this

• Participants leaving the studies early (any reason), proportion

  no effect

  The percentages of participants leaving the studies early were similar (36.5% in quetiapine group and 36.9% in typical antipsychotics group)

  PMID:23728667 · one of two readings recorded this

• Positive symptoms

  no effect, n = 1934

  no significant difference in positive symptoms (PANSS positive subscore: 22 RCTs, n = 1934, MD 0.02 CI -0.39 to 0.43, moderate quality evidence)

  PMID:23728667 · one of two readings recorded this

• Prolactin level

  decreases, n = 1034

  lower prolactin level (4 RCTs, n = 1034, MD -16.20 CI -23.34 to -9.07, moderate quality evidence)

  PMID:23728667 · one of two readings recorded this

• Weight gain

  decreases, n = 866

  less weight gain compared with some typical antipsychotics in the short term (9 RCTs, n = 866, RR 0.52 CI 0.34 to 0.80, NNTH 8, CI 6 to 15)

  PMID:23728667 · one of two readings recorded this

• cholesterol increase

  increases, n = 1473

  6 RCTs, n = 1473, MD 8.57, CI 4.85 to 12.29

  PMID:24249315 · one of two readings recorded this

• PANSS total endpoint score

  increases, n = 1486

  vs olanzapine: 11 RCTs, n = 1486, mean quetiapine endpoint score 3.67 higher, CI 1.95 to 5.39, low quality

  PMID:24249315 · one of two readings recorded this

• PANSS total endpoint score

  increases, n = 319

  vs paliperidone: 1 RCT, n = 319, mean quetiapine endpoint score 6.30 higher, CI 2.77 to 9.83, moderate quality

  PMID:24249315 · one of two readings recorded this

• PANSS total endpoint score

  increases, n = 2155

  vs risperidone: 13 RCTs, n = 2155, mean quetiapine endpoint score 1.74 higher, CI 0.19 to 3.29, moderate quality

  PMID:24249315 · one of two readings recorded this

• prolactin increase

  decreases, n = 319

  1 RCT, n = 319, MD -49.30, CI -57.80 to -40.80

  PMID:24249315 · one of two readings recorded this

• prolactin increase

  decreases, n = 1733

  7 RCTs, n = 1733, MD -35.25, CI -43.59 to -26.91

  PMID:24249315 · one of two readings recorded this

• QTc prolongation

  increases, n = 643

  3 RCTs, n = 643, MD 4.81, CI 0.34 to 9.28

  PMID:24249315 · one of two readings recorded this

• stopping quetiapine within a few weeks

  most people who start quetiapine stop taking it within a few weeks (around 60%)

  PMID:24249315 · one of two readings recorded this

• use of antiparkinson medication

  decreases, n = 1127

  7 RCTs, n = 1127, RR use of antiparkinson medication 0.51, CI 0.32 to 0.81, moderate quality

  PMID:24249315 · one of two readings recorded this

• use of antiparkinson medication

  decreases, n = 319

  1 RCT, n = 319, RR use of antiparkinson medication 0.64, CI 0.45 to 0.91, moderate quality

  PMID:24249315 · one of two readings recorded this

• use of antiparkinson medication

  decreases, n = 2163

  8 RCTs, n = 2163, RR use of antiparkinson medication 0.5, CI 0.36 to 0.69, moderate quality

  PMID:24249315 · one of two readings recorded this

• use of antiparkinson medication

  decreases, n = 522

  1 RCT, n = 522, RR use of antiparkinson medication 0.43, CI 0.2 to 0.93, moderate quality

  PMID:24249315 · one of two readings recorded this

• weight gain of 7% or more of total body weight

  no effect, n = 319

  1 RCT, n = 319, RR weight gain of 7% or more of total body weight 2.52, CI 0.5 to 12.78, moderate quality

  PMID:24249315 · one of two readings recorded this

• weight gain

  decreases, n = 1667

  8 RCTs, n = 1667, RR 0.68, CI 0.51 to 0.92, moderate quality

  PMID:24249315 · one of two readings recorded this

• weight gain

  increases, n = 754

  2 RCTs, n = 754, RR 2.22, CI 1.35 to 3.63, moderate quality

  PMID:24249315 · one of two readings recorded this

• anxiety, change in Hamilton Anxiety Rating Scale (HAM-A)

  MD -2.44 (95% CI -3.34 to -1.55)

  Not recorded as a finding: no outcome node for HAM-A

  There was a significant difference, favoring quetiapine, in the change of the HAM-A (MD −2.44, 95% CI −3.34 to −1.55).

  PMID:25028535 · one of two readings recorded this

• at least one adverse event

  increases

  The participants having at least one adverse event was significantly higher in the quetiapine group (RR 1.18, 95% CI 1.12 to 1.25; number needed to harm [NNH] 13, 95% CI 9 to 26)

  PMID:25028535 · one of two readings recorded this

• at least one adverse event

  increases

  The subgroup analysis showed that the significant difference was found only in the subgroup treated with quetiapine 300 mg/day (RR 1.21, 95% CI 1.13 to 1.30)

  PMID:25028535 · one of two readings recorded this

• at least one adverse event

  no effect

  but not in that with quetiapine 600 mg/day (RR 1.21, 95% CI 0.97 to 1.51)

  PMID:25028535 · one of two readings recorded this

• at least one serious adverse event

  no effect

  no significant difference between quetiapine and placebo in the likelihood of having at least one serious adverse event (RR 0.85, 95% CI 0.49 to 1.48)

  PMID:25028535 · one of two readings recorded this

• CGI-I endpoint score

  decreases

  There was a significant difference, favoring the quetiapine group, in the change in scores of both the CGI-S/CGI-BP-S (MD −0.45, 95% CI −0.56 to −0.34) and the CGI-I (MD −0.62, 95% CI −0.76 to −0.49)

  PMID:25028535 · one of two readings recorded this

• change in CDRS-R total score

  no effect

  no significant difference between quetiapine and placebo on the change in total score of the Children’s Depression Rating Scale™-Revised (CDRS-R) in child and adolescent participants (MD −1.82, 95% CI −5.98 to 2.34)

  PMID:25028535 · one of two readings recorded this

• change in CGI-BP-S score

  decreases

  quetiapine was superior to placebo with respect to change in CGI-BP-S scores (MD −0.26, 95% CI −0.51 to −0.02)

  PMID:25028535 · one of two readings recorded this

• change in CGI-S/CGI-BP-S

  decreases

  There was a significant difference, favoring the quetiapine group, in the change in scores of both the CGI-S/CGI-BP-S (MD −0.45, 95% CI −0.56 to −0.34) and the CGI-I (MD −0.62, 95% CI −0.76 to −0.49)

  PMID:25028535 · one of two readings recorded this

• change in depression rating scale scores (MADRS and CDRS-R)

  decreases

  MADRS and the CDRS-R depression rating scales at the end of the studies (MD −4.66, 95% CI −5.59 to −3.73)

  PMID:25028535 · one of two readings recorded this

• change in depression rating scale scores (MADRS and CDRS-R)

  decreases

  The mean differences with quetiapine 300 mg/day and quetiapine 600 mg/day were superior to those with placebo (MD –4.72, 95% CI −6.02 to −3.42 and MD −4.92, 95% CI −6.32 to −3.51, respectively)

  PMID:25028535 · one of two readings recorded this

• change in depression rating scale scores (MADRS and CDRS-R)

  decreases

  The mean differences with quetiapine 300 mg/day and quetiapine 600 mg/day were superior to those with placebo (MD –4.72, 95% CI −6.02 to −3.42 and MD −4.92, 95% CI −6.32 to −3.51, respectively)

  PMID:25028535 · one of two readings recorded this

• change in HAM-A anxiety score

  decreases

  There was a significant difference, favoring quetiapine, in the change of the HAM-A (MD −2.44, 95% CI −3.34 to −1.55)

  PMID:25028535 · one of two readings recorded this

• change in HAM-A anxiety score

  decreases

  Excluding this study, there was no heterogeneity, and there was a significant difference, favoring quetiapine (MD −2.89, 95% CI −3.55 to −2.22)

  PMID:25028535 · one of two readings recorded this

• change in MADRS/CDRS-R depression rating scale scores, quetiapine versus placebo

  decreases, MD -4.66, 95% CI -5.59 to -3.73

  Not recorded as a finding: No outcome node for MADRS or the pooled MADRS/CDRS-R change (hdrs-total-score names the HDRS)

  There was a significant difference, favoring quetiapine, on the change in scores of the MADRS and the CDRS-R depression rating scales at the end of the studies (MD −4.66, 95% CI −5.59 to −3.73).

  PMID:25028535 · one of two readings recorded this

• change in MADRS score

  decreases, p = 0.013

  significantly greater changes in the MADRS scores than the lithium group (MD −2.49) (P=0.013)

  PMID:25028535 · one of two readings recorded this

• change in MADRS score

  decreases

  At week 8, there was no significant difference in the change of MADRS score between the quetiapine and the sertraline groups (MD −19.4, 95% CI −24.2 to −14.5 and MD −18.2, 95% CI −24.8 to −11.6, respectively)

  PMID:25028535 · one of two readings recorded this

• change in MADRS score

  decreases

  At week 8, there was no significant difference in the change of MADRS score between the quetiapine and the sertraline groups (MD −19.4, 95% CI −24.2 to −14.5 and MD −18.2, 95% CI −24.8 to −11.6, respectively)

  PMID:25028535 · one of two readings recorded this

• change in MADRS total score

  no effect, p = 0.334

  There was no significant difference in the change of MADRS total scores at week 8 between the quetiapine and the combination treatment groups (MD −21.6 and −21.9, respectively) (P=0.334)

  PMID:25028535 · one of two readings recorded this

• change in PSQI sleep quality score

  decreases

  Participants receiving quetiapine were significantly improved in terms of quality of sleep (MD −2.31, 95% CI −2.95 to −1.66)

  PMID:25028535 · one of two readings recorded this

• change in Q-LES-Q SF quality of life score

  increases

  Three studies used the Q-LES-Q SF for the assessment of quality of life and found the superiority of quetiapine in terms of the change scores (MD 2.95, 95% CI 1.70 to 4.20)

  PMID:25028535 · one of two readings recorded this

• change in scores of depression rating scales, MADRS and CDRS-R pooled, quetiapine vs placebo

  MD -4.66 (95% CI -5.59 to -3.73)

  Not recorded as a finding: no outcome node for MADRS or CDRS-R change score

  There was a significant difference, favoring quetiapine, on the change in scores of the MADRS and the CDRS-R depression rating scales at the end of the studies (MD −4.66, 95% CI −5.59 to −3.73).

  PMID:25028535 · one of two readings recorded this

• change in SDS disability score

  decreases

  There was a significant difference, favoring quetiapine, in the change of SDS scores (MD −1.42, 95% CI −2.32 to −0.53)

  PMID:25028535 · one of two readings recorded this

• constipation

  increases

  constipation (RR 2.05, 95% CI 1.50 to 2.81; NNH 25, 95% CI 18 to 41)

  PMID:25028535 · one of two readings recorded this

• diarrhea

  no effect

  The incidence rates of nausea and diarrhea were not significantly different between the quetiapine and placebo groups (RR 0.77, 95% CI 0.56 to 1.07 and RR 0.64, 95% CI 0.40 to 1.01, respectively)

  PMID:25028535 · one of two readings recorded this

• dizziness

  increases

  dizziness (RR 2.18, 95% CI 1.73 to 2.74; NNH 14, 95% CI 11 to 20)

  PMID:25028535 · one of two readings recorded this

• dropout due to adverse events

  increases

  dropouts due to adverse events were significantly higher in the quetiapine group (RR 1.88, 95% CI 1.20 to 2.96)

  PMID:25028535 · one of two readings recorded this

• dropout due to inefficacy

  decreases

  dropouts due to inefficacy were significantly lower in the quetiapine group (RR 0.31, 95% CI 0.19 to 0.53)

  PMID:25028535 · one of two readings recorded this

• dropout for any reason

  no effect

  dropout rates were not significantly different between groups (RR 0.99, 95% CI 0.88 to 1.13)

  PMID:25028535 · one of two readings recorded this

• dry mouth

  increases

  dry mouth (RR 3.65, 95% CI 3.04 to 4.40; NNH 5, 95% CI 4 to 6)

  PMID:25028535 · one of two readings recorded this

• extrapyramidal side effects

  increases

  extrapyramidal side effects (RR 2.77, 95% CI 2.12 to 3.62; NNH 8, 95% CI 7 to 10)

  PMID:25028535 · one of two readings recorded this

• fatigue

  increases

  fatigue (RR 1.57, 95% CI 1.16 to 2.13; NNH 35, 95% CI 21 to 132)

  PMID:25028535 · one of two readings recorded this

The whole record — 468 rows